Shares of Panacea Biotec today rose by over 4 per cent after the company said it has received final approval from the US health regulator to launch generic Prasugrel tablets, used for preventing blood clots in people with acute coronary syndrome, in the American market.
The stock gained 4.21 per cent to close at Rs 248.95 on BSE. During the day, it zoomed 15.48 per cent to Rs 275.90.
On NSE, shares of the company rose 4.25 per cent to end at Rs 247.35.
In terms of equity volume, 2.54 lakh shares of the company were traded on BSE and over 13 lakh shares changed hands on NSE during the day.
"The company's first-to-file abbreviated new drug application (ANDA) of Prasugrel 5 mg and 10 mg tablets has been approved by the US Food and Drug Administration (USFDA)," Panacea Biotec said in a BSE filing.
The tablets are generic version of Eli Lilly's Effient tablets, it added.
Panacea Biotec Joint MD Rajesh Jain said: "Approval and launch of this first to file ANDA product is an important milestone to achieve growth in our US business.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)